Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
72 studies found for:    Open Studies | "Conjunctivitis"
Show Display Options
Rank Status Study
21 Recruiting Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
Conditions: Dry Eye Syndromes;   Keratoconjunctivitis Sicca
Interventions: Drug: KPI-121 0.25% Ophthalmic Suspension;   Drug: Vehicle of KPI-121 0.25% Ophthalmic Suspension
22 Recruiting Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Conditions: Dry Eye Syndromes;   Keratoconjunctivitis Sicca
Interventions: Drug: KPI-121 0.25% Ophthalmic Suspension;   Drug: Vehicle of KPI-121 0.25% Ophthalmic Suspension
23 Recruiting Sanitation, Water, and Instruction in Face-washing for Trachoma
Condition: Trachoma
Interventions: Behavioral: Water, sanitation, and hygiene (WASH) intervention;   Behavioral: Standard of care WASH intervention;   Drug: Azithromycin;   Drug: Tetracycline;   Other: Control
24 Recruiting Water Uptake for Health in Amhara Pilot
Condition: Trachoma
Intervention: Behavioral: instruction in soap-making and hygiene education
25 Recruiting Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Conditions: Infection;   Hypertension;   Pain;   Reflux;   Edema;   Hyperlipidemia;   Hypotension;   Hypercholesterolemia;   Sedation;   Anxiolysis;   Benzodiazepine Withdrawal;   Bipolar Disorder;   Autistic Disorder;   Schizophrenia;   Influenza Treatment or Prophylaxis;   Acute Decompensated Heart Failure;   Stable Angina;   Life-threatening Fungal Infections;   Nosocomial Pneumonia;   Community Acquired Pneumonia;   Acute Bacterial Exacerbation of Chronic Bronchitis;   Complicated Skin and Skin Structure Infections;   Uncomplicated Skin and Skin Structure Infections;   Chronic Bacterial Prostatitis;   Complicated Urinary Tract Infections;   Acute Pyelonephritis;   Uncomplicated Urinary Tract Infections;   Inhalational Anthrax (Post-Exposure);   Infantile Hemangioma;   Withdrawal;   Inflammation;   Bacterial Septicemia;   Cytomegalovirus Retinitis;   Herpes Simplex Virus;   Adenovirus;   Brain Swelling;   Airway Swelling;   Adrenal Insufficiency;   Anxiety;   Nausea;   Vomiting;   Convulsions;   Muscle Spasms;   Seizures;   Epilepsy;   Bartonellosis;   Brucellosis;   Cholera;   Plague;   Psittacosis;   Q Fever;   Relapsing Fever;   Rocky Mountain Spotted Fever;   Trachoma;   Tularemia;   Typhus Fever;   Bronchospasm;   Cardiac Arrest;   Hypersensitivity Reaction;   Cyanide Poisoning;   Acute Bacterial Sinusitis;   Bacterial Meningitis;   Sepsis;   Gastroparesis;   Opioid Addiction;   Migraines;   Headaches
Intervention: Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
26 Recruiting Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease
Condition: Dry Eye
Interventions: Drug: OmegaD;   Drug: Placebo
27 Recruiting Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
Condition: Dry Eye Disease
Interventions: Drug: P-321 Ophthalmic Solution;   Drug: P-321 Ophthalmic Solution placebo
28 Recruiting Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
Condition: Tear Deficient Dry Eye Disease.
Interventions: Drug: P-321 Ophthalmic Solution;   Drug: P-321 Ophthalmic Solution placebo
29 Not yet recruiting A Dose-Finding Study Comparing InSite Vision, Inc. 101 to Vehicle and DuraSite Alone for Dry Eye Disease
Condition: Dry Eye Disease
Intervention: Drug: ISV 101
30 Recruiting Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator
Conditions: Dry Eye Syndrome;   Keratoconjunctivitis Sicca
Intervention: Device: Oculeve Intranasal Neurostimulator
31 Not yet recruiting Three Dimension Tomography of Eye Structures by White Light Imaging Device
Conditions: Healthy Subjects;   Moderate to Severe Keratoconjunctivitis Sicca (KCS);   Dry Eye Syndrome (DES)
Intervention: Device: None invasive imaging of the tear film (AdOM)
32 Not yet recruiting An 8-week Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye
Condition: Dry Eye
Interventions: Drug: NGF;   Other: Vehicle
33 Not yet recruiting PILOT STUDY FOR TESTING SAFETY OF REPETITIVE MAGNETIC STIMULATION FOR TREATMENT OF DRY EYE
Condition: Dry Eye
Intervention: Device: repeated magnetic stimulation (RMS) treatment to the eye
34 Not yet recruiting Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity
Condition: Dry Eye
Intervention: Device: Intense Pulse Light Energy delivery (IPL)
35 Recruiting Comparison of the Clinical Effects of Two Tear Substitutes in Patients With Dry Eye Syndrome
Condition: Dry Eye
Interventions: Drug: Liposic;   Drug: Tears Naturale Forte
36 Not yet recruiting A Study to Evaluate the Performance and Safety of CBL-101 Versus Vismed® Multi Eye Drops in the Management of Dry Eye
Condition: Dry Eye
Interventions: Device: CBL-101 Eye Drops;   Device: Vismed® Multi
37 Recruiting Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
Condition: Dry Eye Syndromes
Interventions: Drug: AGN-195263;   Drug: Vehicle
38 Not yet recruiting Efficacy Comparison of Two Kinds of Treatment in Treating Dry Eye Caused by Meibomian Gland Dysfunction
Condition: Dry Eye Syndrome
Interventions: Device: intense pulsed light;   Drug: Tobramycin and Dexamethasone Ophthalmic Ointment
39 Recruiting Topical Omega-3 Fatty Acids (REMOGEN® OMEGA) in the Treatment of Dry Eye
Condition: Dry Eye Syndromes
Interventions: Device: REMOGEN OMEGA;   Device: Povidone
40 Not yet recruiting A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye
Condition: Dry Eye Syndromes
Interventions: Drug: Omega 3;   Drug: Optive Advanced;   Drug: Optive

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.